UnitedHealth Lifts Outlook After a $610M Claims Revision

By Stock Titan Editorial Team Published October 13, 2026, 06:27 AM EDT

UnitedHealth’s third quarter results and raised outlook

UnitedHealth earned far more than a year ago on slightly less revenue. In the three months to September 30, 2026, the company reported revenue of $112.7 billion against $113.2 billion a year earlier, earnings from operations of $6.6 billion against $4.3 billion, and adjusted earnings per share of $4.69 against $2.92, according to its third quarter 2026 results release. Earnings per share under GAAP, the standard accounting rules, were $4.56. Adjusted figures leave out items such as the amortization of acquired intangible assets and gains on businesses it sold (our guide to GAAP and non-GAAP earnings explains the difference).

Both halves of the company contributed. UnitedHealthcare, the insurance business, earned $2.8 billion from operations against $1.8 billion, and Optum, which runs clinics, pharmacy benefits and data services, earned $3.7 billion against $2.5 billion, so the insurer supplied about $1.0 billion of the $2.2 billion increase and Optum about $1.2 billion.

For the insurance side, the measure that matters most is the medical care ratio, the share of every premium dollar that goes out again to pay for members’ care. UnitedHealth’s was 88.4%, down from 89.9% in the third quarter of 2025, which means it kept about 11.6 cents of each premium dollar before its own running costs, against about 10.1 cents a year earlier. The company credits “medical cost management initiatives, benefit design changes and pricing discipline, as well as care delivery enhancements focused on affordability and integrated value-based care.”

It also raised its outlook for 2026 for the third time this year. It now expects adjusted earnings of at least $20.50 per share and GAAP earnings of at least $19.50, after a July range of $19.50 to $20.00 on the adjusted measure. The company also filed the release with the SEC as an exhibit to a Form 8-K and posts it as a PDF on its investor site. The company’s conference call was scheduled for 8:00 a.m. ET, after this was written, and no regular trading session had taken place since the release.

Lower estimates for earlier claims supplied 0.7 points

Nearly half of the drop in the ratio came from lowering cost estimates made earlier in the year. The release says the ratio “was impacted by $610 million of net favorable prior period reserve development related to 2026 dates of service.” Put that $610 million back into the quarter’s medical costs of $76,982 million and divide by premiums of $87,078 million, and the ratio comes to 89.1%, which is 0.7 points higher than the 88.4% reported (our calculation). The reported ratio fell 1.5 points from a year earlier, so the release accounts for a little under half of the fall.

Some background helps here. An insurer does not know its full medical bill when a quarter ends, because doctors and hospitals send many claims weeks or months later. So it books an estimate for care already given but not yet billed, called a reserve. When those claims arrive and cost less than the estimate, the difference lowers the medical costs of the quarter in which the insurer finds out. That is favorable development. Insurers revise these estimates as claims come in, so some development in one direction or the other is routine; what makes this one worth a look is its size.

Show the data

Category	Change
Q2 2025	-0.1 pts
Q3 2025	+0.1 pts
Q2 2026	+1.0 pts
Q3 2026	+0.7 pts

A year earlier the same line was tiny. The third quarter 2025 release reported $80 million of favorable development, so on the same basis the year-earlier ratio was 90.0%. Comparing like with like, the ratio improved by about 0.8 points, a little more than half of the 1.5 points the headline numbers show; measured that way, the difference between the two years’ reserve releases accounts for about 42% of the improvement.

The second quarter of 2026 carried even more: the second quarter release reported $860 million of favorable development, “with the majority related to 2026 dates of service,” and the 86.7% ratio of that quarter would have been about 87.7% without it. Two quarters in a row, then, care delivered earlier in the year has turned out to cost noticeably less than UnitedHealth first booked.

In earnings terms, $610 million is worth roughly $0.53 per share after tax, if we apply the quarter’s effective tax rate of 22.2% and divide by 902 million diluted shares. That would put adjusted earnings per share near $4.16 in place of $4.69. Done the same way for the year-earlier quarter, its $80 million was worth about $0.07, so on that basis $4.16 compares with about $2.85, roughly 46% higher. The quarter is much better than a year ago with the releases taken out; it is just less spectacular than the headline suggests. A separate item, a $95 million reduction in reserves the company set aside for loss-making contracts, is excluded from adjusted earnings, so it does not sit inside the $4.69.

The phrase “2026 dates of service” matters for the year as a whole. These were claims for care given earlier in 2026, whose costs had been booked in earlier quarters. Lowering them in the third quarter puts the correction in a different quarter from the care it relates to, so the earlier months looked more expensive than they turned out to be and the third quarter looks cheaper. Results for the nine months together carry the updated estimate whichever quarter it landed in, which makes them less sensitive to that timing: medical costs of $225,829 million on premiums of $261,595 million give a ratio of 86.3% for January to September 2026, against 88.1% for the same months of 2025 (our calculation from the release).

The better ratio does not show cheaper care

A lower medical care ratio means premiums rose faster than the bills, or the bills fell faster than premiums, and the ratio alone cannot say which. UnitedHealth’s own explanation lists pricing and benefit design alongside medical cost management. It names “benefit design changes and pricing discipline” among the reasons for the lower ratio, and says UnitedHealthcare’s higher earnings were “driven by benefit changes and pricing discipline, combined with medical and operating cost management.”

What the company has said about the cost of care itself has not described a slowdown. Its first quarter 2026 release said the improvement then was “partially offset by consistently elevated utilization and unit cost trends,” meaning people were using more care and each service cost more. The third quarter release does not update that description.

The totals do not settle the question either. Medical costs for the quarter fell 3.7%, from $79,958 million to $76,982 million, while the number of people in the plans where UnitedHealth carries the cost of care fell 8.8%, from 28.6 million to 26.1 million (our sum of commercial risk-based, Medicare Advantage, Medicaid and Medicare Supplement members at September 30 of each year). These totals cover different populations (the consolidated figures also include stand-alone Medicare drug plans, businesses held for sale and other lines the member count leaves out, and the mix of members changed), so they do not establish whether medical spending per person rose or fell.

So the answer to the question most readers bring to this release is fairly plain. The recovery in UnitedHealth’s margins is real, and most of it survives taking out the reserve release. By the company’s own description it rests on pricing and benefit design alongside cost management, and it came while UnitedHealth covered fewer people. Nothing in the release shows that health care itself got cheaper.

UnitedHealth covers 1.8 million fewer people

UnitedHealthcare served 48.3 million people in its medical plans at September 30, 2026, against 50.1 million a year earlier, so 1.8 million fewer. The losses are concentrated in the plans where the insurer pays the bills. Commercial plans it insures (employer and individual coverage) fell by 865,000 people, Medicare Advantage by 830,000 and Medicaid by 765,000. Commercial plans that pay their own claims and use UnitedHealthcare to run them grew by 690,000, which is why the total fell less than the insured book.

Show the data

Category	Change
Commercial plans, fee-based	+690
Medicare Supplement	-55
Medicaid	-765
Medicare Advantage	-830
Commercial plans, risk-based	-865

The release gives reasons for some of it. It says seniors “served through Medicare Advantage, including programs serving complex populations included in Medicaid, have contracted by 935,000 since year-end 2025,” a measure counted from December, while the chart covers twelve months, and Medicare and retirement revenue fell to $42.4 billion from $43.4 billion “due to changes in membership and product mix.” The Medicare Advantage line did tick up by 40,000 between June and September, to 7.605 million from 7.565 million.

Medicaid membership fell 85,000 in the quarter “due to ongoing Medicaid eligibility changes,” and the employer and individual business lost 165,000 people in the quarter “due to employer attrition.” For the individual plans sold under the Affordable Care Act, UnitedHealth repeats a pledge to give up its 2026 profit on those plans: it says it is “returning this money directly to approximately 1 million ACA members.”

The same pattern shows up inside Optum. Optum Health’s earnings from operations rose to $735 million from $41 million, while its revenue fell 10% to $22.9 billion “as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians.” Optum Rx filled 393 million adjusted prescriptions against 414 million, which the release puts down to “membership declines within UnitedHealthcare and other customers.” The release does not say where former members went or what their care costs now, so a smaller book at UnitedHealth tells a reader nothing about lower costs across the health system.

The raised outlook leaves at least $2.20 for the fourth quarter

The new floor of $20.50 leaves roughly $2.20 of adjusted earnings per share for the fourth quarter, because the company has already earned $18.30 in the first nine months ($7.23, $6.38 and $4.69 by quarter). That is about 4% above the $2.11 of the fourth quarter of 2025 reported in the 2025 results release, and less than half of what the company earned in the third quarter. The $2.20 is an implication of the company’s own outlook, which is an expectation and not a guarantee, and it is not a forecast of ours; the full-year and quarterly per-share figures also use slightly different share counts, so the subtraction is approximate.

Show the data

Category	Value
Jan 27	$17.75
Apr 21	$18.25
Jul 16	$19.50
Oct 13	$20.50

The last quarter was also UnitedHealth’s weakest of 2025, $2.11 of adjusted earnings per share against $2.92 in the third. Its reported medical care ratio for those three months was 92.4%, or 91.5% on the company’s adjusted basis, which leaves out charges for loss-making contracts, against 89.1% reported and 88.9% adjusted for the full year. A floor of $2.20 is therefore a modest step up on what was the weakest quarter of 2025.

The path of the floor matters too. UnitedHealth began 2026 guiding to more than $17.75, raised that to more than $18.25 in April, set a range of $19.50 to $20.00 in July and now says at least $20.50. That is a different rhythm from 2025, when it started at $29.50 to $30.00 (January 2025 release), cut the range in April (April 2025 release), suspended the outlook in May (July 2025 release) and finished the year at $16.35 of adjusted earnings per share. Readers who want the vocabulary of guidance against analysts’ expectations can find it in our explainer on guidance and consensus estimates.

Rival insurers gave mixed signals on medical costs in the second quarter

UnitedHealth reports eight days before Elevance Health, the next of the large insurers whose dates we checked, so for now its numbers are the freshest reading on the July to September quarter. Elevance releases its third quarter results on October 21 at 6:00 a.m. EDT, according to its notice, and Molina Healthcare follows after the market closes the same day (Molina notice). CVS Health holds its call on November 4 (CVS notice), Cigna reports on November 5 (Cigna notice) and Humana on November 6 (Humana notice).

Their second quarter reports, the latest available, did not tell one story. Elevance said its benefit expense ratio of 89.7% “increased 80 basis points year over year, driven by expected elevated medical cost trend in our Government businesses, partially offset by improved performance in Individual ACA compared to the prior year” (Elevance second quarter release). Molina’s medical care ratio rose to 92.2% from 90.4% (Molina release).

Centene’s health benefits ratio fell to 89.6% from 93.0%, which it tied to “improved pricing and risk transfer” in its Marketplace plans (Centene release), and Humana’s insurance segment benefit ratio of 91.2% was “in line with management’s guidance” (Humana release). Each company defines its ratio a little differently and their mixes of Medicare, Medicaid and employer business differ widely, so the four figures are not a league table.

The people who pay the premiums have been feeling the cost of care from the other side. KFF’s 2025 employer survey found that “annual premiums for employer-sponsored family health coverage reached $26,993 this year, 6% higher than in 2024,” and that “on average, workers contributed $6,850 toward the cost of family coverage” (KFF 2025 Employer Health Benefits Survey).

For Medicare Advantage, the government sets the payment rates. In its final rate announcement for 2027, the Centers for Medicare & Medicaid Services projected “an increase of 2.48% or over $13 billion in payments to MA plans” in 2027, or 4.98% when it accounts for the expected rise in members’ recorded risk scores (CMS 2027 rate announcement fact sheet). These are projected national average payment changes, not UnitedHealth’s own expected increase; its Medicare and retirement business, which includes them, brought in $42.4 billion of revenue this quarter.

Signs that would show the recovery turning

A few markers would tell a reader whether UnitedHealth’s improvement is holding, and they are all in documents still to come. One is whether the fourth quarter brings more favorable reserve development or the opposite. Two large favorable releases in a row mean the early estimates for 2026 ran above the claims that came in; a swing to unfavorable development, like the $70 million it reported for the second quarter of 2025 in its July 2025 release, would mean costs ran ahead of its estimates again.

Another is what peers report for the same quarter. Ratios that improve at Elevance, Centene and Humana once reserve effects are set aside would point to a margin recovery across the industry, and their own explanations of pricing, benefits and cost trend would show what drove it. Worsening peer ratios would suggest UnitedHealth’s recovery was less widely shared, and separate disclosures would be needed to explain why.

Then there is the 2027 outlook, which UnitedHealth has not given in this release; the 2026 outlook came in January, with the 2025 results. Days claims payable, a measure of how many days of medical bills the insurer holds in reserve, stood at 47.0 at the end of September, the same as in June and up from 46.2 a year earlier; a fall would point to thinner reserves relative to the costs it reports.

Method and inputs for our calculations

Every input comes from UnitedHealth’s own releases as stored on StockTitan, read on October 13, 2026. The medical care ratio is medical costs divided by premiums. Without reserve development, the third quarter 2026 ratio is ($76,982 million plus $610 million) divided by $87,078 million, or 89.1%; the third quarter 2025 ratio is ($79,958 million plus $80 million) divided by $88,979 million, or 90.0%; the second quarter 2026 ratio is ($75,358 million plus $860 million) divided by $86,956 million, or 87.7%. The reserve chart divides each quarter’s development by that quarter’s premiums, including $70 million of unfavorable development on $87,905 million of premiums for the second quarter of 2025.

The per-share value of $610 million is $610 million times one minus the quarter’s effective tax rate (income taxes of $1,224 million on pre-tax earnings of $5,524 million, 22.2%), divided by 902 million diluted shares; the year-earlier $80 million uses the same method with taxes of $686 million on $3,229 million and 908 million shares. Risk-based members are the sum of commercial risk-based, Medicare Advantage, Medicaid and Medicare Supplement members in the release’s people served table: 26,120,000 at September 30, 2026 and 28,635,000 a year earlier. The fourth quarter figure is the $20.50 outlook minus the $18.30 of adjusted earnings per share for the first nine months. Our editorial policy describes how we source and check figures.

Frequently asked questions

The information provided in this article is for educational and informational purposes only. It does not constitute financial advice, investment recommendation, or an endorsement of any particular investment strategy. Past performance does not guarantee future results. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now